In March, members of the CTF staff were treated to a talk by Synodos for NF1 Principal Investigator Jill Weimer, PhD, of the Sanford School of Medicine. Dr. Weimer discussed the swine model program currently underway, which we hope will lead to a more accurate screening of drugs to treat NF1. Click thru for a transcript of her talk.
Neurofibromatosis (NF) knows no boundaries, and while the Children’s Tumor Foundation (CTF) is based in the United States, its work is global, funding and collaborating with the best researchers on the planet working on NF. In that spirit, we highly applaud the efforts of the Innovative Medicines Initiative (IMI). The IMI, based in Brussels - Belgium, is a public private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations that facilitates research collaboration in order to advance the development of medical treatments.
Earlier this month, more than 70 researchers, clinicians, patients, staff, and other experts gathered in Palm Beach, Florida for the first Synodos Network Meeting, hosted by the Children’s Tumor Foundation.
Each year, the National Cancer Institute (NCI) prepares a report to communicate to the President and to Congress NCI’s research priorities, progress made to date, scientific areas of opportunity that will advance cancer research and improve patients’ lives, and the funding needed to do so. This year, the FY2019 report included stories to highlight how investments in cancer research help people living longer and healthier lives. One of these stories is a profile of NF Hero Philip Moss.
The Children’s Tumor Foundation (CTF) and the scientific journal PLOS ONE are collaborating on a new funding program in the area of neurofibromatosis (NF) research. The new initiative, called the Drug Discovery Initiative Registered Report (DDIRR) 2017 Awards, is a funder-publisher partnership to integrate the Registered Reports model in the grant application process.